Supernus Pharmaceuticals Statistics
Share Statistics
Supernus Pharmaceuticals has 55.22M shares outstanding. The number of shares has increased by 0.87% in one year.
| Shares Outstanding | 55.22M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 52.88M |
| Failed to Deliver (FTD) Shares | 51 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 6.80M, so 12.32% of the outstanding shares have been sold short.
| Short Interest | 6.80M |
| Short % of Shares Out | 12.32% |
| Short % of Float | 12.87% |
| Short Ratio (days to cover) | 24.57 |
Valuation Ratios
The PE ratio is 1199.3 and the forward PE ratio is 19.67.
| PE Ratio | 1199.3 |
| Forward PE | 19.67 |
| PS Ratio | 2.6 |
| Forward PS | 3.2 |
| PB Ratio | 1.71 |
| P/FCF Ratio | 14.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Supernus Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.54B.
| EV / Earnings | 1173.82 |
| EV / Sales | 2.54 |
| EV / EBITDA | 17.16 |
| EV / EBIT | -293.18 |
| EV / FCF | 13.98 |
Financial Position
The company has a current ratio of 1.7, with a Debt / Equity ratio of 0.
| Current Ratio | 1.7 |
| Quick Ratio | 1.43 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -2.18 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is -0.26%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -0.26% |
| Revenue Per Employee | 931.78K |
| Profits Per Employee | 2.02K |
| Employee Count | 652 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.08 |
Taxes
| Income Tax | 1.45M |
| Effective Tax Rate | 0.52 |
Stock Price Statistics
The stock price has increased by 32.7% in the last 52 weeks. The beta is 0.87, so Supernus Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.87 |
| 52-Week Price Change | 32.7% |
| 50-Day Moving Average | 35.12 |
| 200-Day Moving Average | 31.66 |
| Relative Strength Index (RSI) | 49.37 |
| Average Volume (20 Days) | 345.67K |
Income Statement
In the last 12 months, Supernus Pharmaceuticals had revenue of $607.52M and earned $1.32M in profits. Earnings per share was $0.02.
| Revenue | 607.52M |
| Gross Profit | 523.74M |
| Operating Income | -5.27M |
| Net Income | 1.32M |
| EBITDA | 90.04M |
| EBIT | -5.27M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has $75.05M in cash and $41.53M in debt, giving a net cash position of $33.53M.
| Cash & Cash Equivalents | 75.05M |
| Total Debt | 41.53M |
| Net Cash | 33.53M |
| Retained Earnings | 482.56M |
| Total Assets | 1.34B |
| Working Capital | 348.50M |
Cash Flow
In the last 12 months, operating cash flow was $111.08M and capital expenditures -$551.00K, giving a free cash flow of $110.53M.
| Operating Cash Flow | 111.08M |
| Capital Expenditures | -551.00K |
| Free Cash Flow | 110.53M |
| FCF Per Share | 2.03 |
Margins
Gross margin is 86.21%, with operating and profit margins of -0.87% and 0.22%.
| Gross Margin | 86.21% |
| Operating Margin | -0.87% |
| Pretax Margin | 0.46% |
| Profit Margin | 0.22% |
| EBITDA Margin | 14.82% |
| EBIT Margin | -0.87% |
| FCF Margin | 18.19% |
Dividends & Yields
SUPN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.06% |
| FCF Yield | 5.54% |
Analyst Forecast
The average price target for SUPN is $36, which is -0.4% lower than the current price. The consensus rating is "Hold".
| Price Target | $36 |
| Price Target Difference | -0.4% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 5.12 |
| Piotroski F-Score | 6 |